Correlation between Increased Serum Vascular Endothelial Growth Factor Levels and 30-Day-Outcome After Acute Myocardial Infarction

Sylvia Youvella, Adi Koesoema Aman, Nizam Akbar

Abstract


Vascular Endothelial Growth Factor (VEGF) plays an important role in the process of regeneration and vascular repair. Atherogenesis and angiogenesis contribute to the formation of coronary collateral circulation as an alternative source of blood supply during the repairing process of Acute Myocardial Infarction (AMI). This study aimed to investigate the elevation of VEGF and its correlation to Peripheral Blood Mononuclear Cells (PBMC) and Major Adverse Cardiovascular st nd th Events (MACE). Serum VEGF measurements were carried out on 1 , 2 , and the 5 -day onset of angina on 20 patients using st th Chemwell Analyzer based on ELISA method. PBMC was counted on days 1 and 5 according to CBC results from Automatic Cell Counter Sysmex XN-1000i. The major adverse cardiovascular event was recorded 30 days after AMI onset. It was found nd that serum VEGF level in this study was 169.3±34.5 pg/mL on the 1st day, 217.0±49.7 pg/mL on the 2 day, and th th 249.2±48.5 pg/mL on the 5 day. Serum VEGF levels increased gradually and the highest value was found on the 5 day st (p=0.000). There was no correlation between elevated serum VEGF levels with PBMC on the 1 day (p=0.429, r=-0.035) and th the 5 day of AMI (p=0.225, r=+0.081). There was no correlation between elevated serum VEGF levels with incidence of MACE on 30 days after onset of AMI (OR=0.959, 95% CI, p=0.302). Serum VEGF concentrations are increased in Acute Myocardial Infarction and can be used as a marker of myocardial injury. However, this study was unable to prove its role in the outcome of AMI

Keywords


Vascular endothelial growth factor, acute myocardial infarction, peripheral blood mononuclear cells, major adverse cardiovascular event

Full Text:

PDF

References


Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ,

et al. Fourth universal definition of myocardial

infarction (2018). Eur Heart J, 2019; 40: 237-269.

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M,

et al. 2015 ESC guidelines for the management of

acute coronary syndromes in patients presenting

without persistent ST-segment elevation: Task force

for the management of acute coronary syndromes in

patients presenting without persistent ST-segment

elevation of the European Society of Cardiology (ESC).

Eur Heart J, 2016; 37: 267-315.

WHO. About cardiovascular diseases. 2015 Available

from: http://www.who.int/cardiovascular_diseases/

about_cvd/en/.[accessed 18 March, 2018].

Kementrian Kesehatan RI. Direktorat Jenderal Penyakit

Tidak Menular. Profil penyakit tidak menular tahun

Jakarta, Kementrian Kesehatan RI, 2017; 92.

Kementrian Kesehatan RI. Penyakit jantung penyebab

kematian terbanyak ke-2 di Indonesia. 2019. Available

from: h ttps ://www. k emk e s .go. id/ a rti c l e /

view/19093000001/penyakit-jantung-penyebab

-kematian-terbanyak-ke-2-di-indonesia.html.

(accessed 14 June, 2021).

Wu X, Reboll MR, Korf-Klingebiel M, Wollert KC.

Angiogenesis after acute myocardial infarction. ESC

Cardiovascular Research, 2021; 117: 1257-1273.

Zou J, Fei Q, Xiao H, Wang H, Liu K, et al. VEGF-A

promotes angiogenesis after acute myocardial

infarction through increasing ROS production and

enhancing ER stress-mediated autophagy. J Cell

Physiol, 2019; 234(10): 17690-703.

Braile M, Marcella S, Cristinziano L, Galdiero MR,

Modestino L, et al. VEGF-A in cardiomyocytes and

heart diseases. Int. J. Mol. Sci, 2020; 21(15): 5294.

Gui C, Zeng ZY, Chen Q, Luo YW, Li L, Chen LL.Neuregulin-1 promotes myocardial angiogenesis in

the rat model of diabetic cardiomyopathy.Cell Physiol

Biochem, 2018; 46(6): 2325-34.

Varricchi G, Lo_redo S, Galdiero MR, Marone G,

Cristinziano L, et al. Innate effector cells in

angiogenesis and lymphangiogenesis. Curr. Opin.

Immunol, 2018; 53: 152–160.

Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran

PR. VEGF-A/VEGFR2 signaling network in endothelial

cells relevant to angiogenesis. J. Cell Commun Signal,

; 10: 347–354.

Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ,

et al. Molecular pharmacology of VEGF-A isoforms:

Binding and signalling at VEGFR2. Int. J. Mol. Sci, 2018;

: 1264.

Hoeres T, Wilhelm M, Smetak M, Holzmann E, Tanzil

GS, et al. Immune cells regulate VEGF signalling via

release of VEGF and antagonistic soluble VEGF

receptor-1. British Society for Immunology, Clinical

and Experimental Immunology, 2017; 192: 54–67.

Alfatni A, Riou M, Charles AL, Meyer A, Barnig C, et al.

Peripheral blood mononuclear cells and platelets

mithocondrial dysfunction, oxidative stress, and

circulating mtDNA in cardiovascular diseases. J. Clin.

Med, 2020; 9: 311.

Simons M, Gordon E, Claesson-Welsh L. Mechanisms

and regulation of endothelial VEGF receptor

signalling. Nat Rev Mol Cell Biol, 2016; 17: 611–625.

Dube KN, Thomas TM, Munshaw S, Rohling M, Riley

PR, Smart N. Recapitulation of developmental

mechanisms to revascularize the ischemic heart. JCI

Insight 2017; 2: e96800.

Garcia R, Bouleti C, Sirol M, Logeart D, Monnot C, et al.

VEGF-A plasma levels are associated with

microvascular obstruction in patients with ST-segment

elevation myocardial infarction. Int J Cardiol, 2019; 291:

-24.

Harada K, Kikuchi R, Ishii H, Shibata Y, Suzuki S, et al.

Association between the ratio of anti-angiogenic

isoform of VEGF-A to total VEGF-A and adverse clinical

outcomes in patients after acute myocardial

infarction. Int J Cardiol Heart Vasc, 2018; 19: 3–7.

Niu J, Han X, Yin J, Zhang Z, Zhang ZT. Correlation

between vascular endothelial growth factor and

long-term prognosis in patients with acute myocardial

infarction. Experimental and Therapeutic Medicine,

; 12(1): 475-479.

Kobayashi K, Maeda K, Takefuji M, Kikuchi R, Morishita

Y, et al. Dynamics of angiogenesis in ischemic areas of

the infarcted heart. Sci Rep, 2017; 7: 7156.

Kurotsu S, Osakabe R, Isomi M, Tamura F, Sadahiro T,

et al. Distinct expression patterns of Flk1 and Flt1 in

the coronary vascular system during development

and after myocardial infarction. Biochem Biophys Res

Commun, 2018; 495: 884–891.

Williams AL, Khadka V, Tang M, Avelar A, Schunke KJ,

et al. HIF1 mediates a switch in pyruvate kinase

isoforms after myocardial infarction. Physiol

Genomics, 2018; 50: 479–494.

Howangyin KY, Zlatanova I, Pinto C, Ngkelo A, Cochain

C, et al. Myeloid-epithelialreproductive receptor

tyrosine kinase and milk fat globule epidermal growth

factor 8 coordinately improve remodeling after

myocardial infarction via local delivery of vascular

endothelial growth factor. Circulation, 2016; 133:

–839.

Ferrara N, Adamis AP. Ten years of anti-vascular

endothelial growth factor therapy. Nat Rev Drug

Discov, 2016; 15: 385–403.

Reinstadler SJ, Thiele H, Eitel I. Risk stratification by

cardiac magnetic resonance imaging after ST-elevation

myocardial infarction. Curr Opin Cardiol, 2015; 30:

–9.

Tiller C, Reindl M, Holzknecht M, Klapfer M, Beck A,

et al. Biomarker assessment for early infarct size

estimation in ST-elevation myocardial infarction.

European Journal of Internal Medicine, 2019; 64: 57-62.

Huang A, Qi X, Cui Y, Wu Y, Zhou S, et al. Serum VEGF:

Diagnostic value of acute coronary syndrome from

stable angina pectoris and prognostic value of

coronary artery disease. Cardiol Res Pract, 2020;

: 6786302




DOI: http://dx.doi.org/10.24293/ijcpml.v27i3.1663

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.